KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Change in Taxes (2021 - 2025)

AbCellera Biologics (ABCL) has disclosed Change in Taxes for 5 consecutive years, with -$10.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Taxes fell 165.44% year-over-year to -$10.1 million, compared with a TTM value of -$29.8 million through Dec 2025, down 548.7%, and an annual FY2025 reading of -$29.8 million, down 548.7% over the prior year.
  • Change in Taxes was -$10.1 million for Q4 2025 at AbCellera Biologics, up from -$12.2 million in the prior quarter.
  • Across five years, Change in Taxes topped out at $70.0 million in Q1 2022 and bottomed at -$87.2 million in Q3 2022.
  • Average Change in Taxes over 5 years is -$4.7 million, with a median of -$3.2 million recorded in 2024.
  • Peak annual rise in Change in Taxes hit 1242.66% in 2022, while the deepest fall reached 11467.01% in 2022.
  • Year by year, Change in Taxes stood at $16.0 million in 2021, then plummeted by 434.78% to -$53.7 million in 2022, then skyrocketed by 103.31% to $1.8 million in 2023, then surged by 763.41% to $15.4 million in 2024, then plummeted by 165.44% to -$10.1 million in 2025.
  • Business Quant data shows Change in Taxes for ABCL at -$10.1 million in Q4 2025, -$12.2 million in Q3 2025, and -$3.2 million in Q2 2025.